obecabtagene autoleucel · Aucatzyl

Cell therapy

Approvedregulatory verdict

Evidence outlook

Approved: Acute Lymphoblastic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
EU
  • Adults 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (conditional marketing authorisation)
Product first approved 2025EMA
UK
  • Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (conditional marketing authorisation)
Product first approved 2025MHRA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Acute Lymphoblastic Leukemia
NCT07400029 · Memorial Sloan Kettering Cancer Center
2026-02-03 – 2029-02 · Acute Lymphoblastic Leukemia
What this study did
Other / comorbidity
NCT07053059 · M.D. Anderson Cancer Center
2025-08-26 – 2030-05-31 · Acute Lymphocytic Leukemia (ALL)
What this study did
NCT07053800 · Autolus Limited
2026-01-16 – 2029-10 · Lupus Nephritis
What this study did
Phase 1/2 (1)
Acute Lymphoblastic Leukemia
Phase 1 (3)
Acute Lymphoblastic Leukemia
NCT06173518 · Autolus Limited
2023-11-16 – 2027-11 · Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
What this study did
Other / comorbidity
NCT07139743 · Autolus Limited
2025-08-04 – 2029-08-15 · Progressive Multiple Sclerosis
What this study did
NCT06333483 · Autolus Limited
2024-02-02 – 2027-09 · Systemic Lupus Erythematosus
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Obecabtagene Autoleucel (Aucatzyl): this drugApprovedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabApprovedMultispecific antibodyCD19 x CD3Weak signal
NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6)
Inebilizumab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Ponatinib (ICLUSIG)ApprovedSmall moleculeBCR-ABL (including T315I)Partial signalFeatured results are non-efficacy only in this race
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budoprutug
Phase 2(overall)
Monoclonal antibodyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT819
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-T
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ZiftomenibPhase 1/2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-319
Phase 1(overall)
Antibody–drug conjugateCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-519
Phase 1(overall)
—CD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
IC19 CAR-T
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
UTAA09
Phase 1(overall)
Cell therapyCD19
Weak signal(overall)
No reviewed efficacy summary in this indication
ZM001
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Vispacabtagene Regedleucel
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Aucatzyl (obecabtagene autoleucel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
Phase 1Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-09 · NCT06333483 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-11 · NCT06173518 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
Phase 2Acute Lymphocytic Leukemia (ALL)Recruiting
Est. primary completion 2028-05-31 · NCT07053059 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Lupus NephritisRecruiting
Est. primary completion 2028-08 · NCT07053800 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-02 · NCT07400029 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2029-06-30 · NCT04404660 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Progressive Multiple SclerosisRecruiting
Est. primary completion 2029-08-15 · NCT07139743 · CT.gov ↗
What to watch

See the full readout calendar ↗